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Abstract
Stomach carcinogenesis involves mucosal and luminal changes that favor spontaneous disappearance of Helicobacter pylori.
Therefore, the association between the infection and cancer risk might typically be underestimated. As acquisition of the
infection almost invariably occurs before adulthood, the serostatus at age 16–40 should best reflect the lifetime occurrence
of the infection. We therefore conducted a case-control study nested within a historic cohort of about 400,000 individuals
who donated sera before age 40 to either of two large Swedish Biobanks between 1968 and 2006, and whose records were
linked to complete nationwide registers. For each stomach adenocarcinoma case occurring at least 5 years after serum
donation 2 controls were selected matched on age, sex and year of donation and biobank. Serum immunoglobulin G
antibodies against H. pylori cell-surface antigens (Hp-CSAs) were measured with an enzyme–linked immunosorbent assay
and antibodies against CagA with an immunoblot assay. Conditional logistic regression models were used to estimate odds
ratios (ORs) for stomach adenocarcinoma among H. pylori infected relative to uninfected. We confirmed 59 incident cases of
stomach adenocarcinoma (41 non-cardia tumors) during follow-up. ORs for non-cardia stomach adenocarcinoma among
subjects with Hp-CSA antibodies (regardless of CagA serostatus), antibodies against CagA (regardless of Hp-CSA serostatus),
and antibodies to both, relative to those who were seronegative to both, were 17.1 (95% confidence interval [CI] 4.0–72.9),
10.9 (95% CI 3.2–36.9), and 48.5 (95% CI 5.8–407.4), respectively. H. pylori infection is a much stronger risk factor for non-
cardia stomach adenocarcinoma than initially realized. However, further studies are needed to answer whether it is a
necessary cause, as the possibility of misclassification of H. pylori status could not be ruled out in our study.
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Introduction
Although the incidence of stomach adenocarcinoma has
declined in the industrialized world, most likely due to the
declining rates of Helicobacter pylori (H. pylori) infections, it is still the
fourth most common type of cancer, and due to the poor prognosis
the second most common cause of cancer-related deaths
worldwide [1,2]. Notwithstanding its epithet as the by far strongest
established risk factor for distal stomach cancer [3], H. pylori
infection has remained a dark horse in regard to its true
attributable fraction, in turn determined by the true strength of
the association. Serological tests of antibodies against H. pylori cell
surface antigens (Hp-CSAs) and CagA encoded by cytotoxin-
associated gene-A, known to cause more extensive inflammation in
the stomach mucosa, have long been employed to explore this
association. However, chronic atrophic gastritis, occurring at a
rate of 0.9–3.6 per 100 person-years among untreated infected
individuals [4] and probably at a much higher rate among those
predestined to develop stomach cancer, destroys the microorgan-
ism’s natural niche and may lead to disappearance of H. pylori and
decreasing antibody titres. This might have resulted in underes-
timation of the strength of the association in previous studies. To
measure H. pylori infection status in early adulthood till 40 years of
age, when essentially all infected people have already acquired
their infection [5] but chronic atrophic gastritis is still rare [6],
would be critical for accurately measuring the true association. We
therefore conducted a case-control study nested within a historic
cohort of about 400 000 individuals who donated serum samples
to either of two large Swedish Biobanks at young ages between
1968 and 2006 to estimate the true strength of the H. pylori-
stomach cancer relationship.
Methods
The cohort included all individuals who donated serum before
40 years of age to either of the two Swedish Biobanks – the
Swedish Institute for Infectious Disease Control Biobank (since
1957) and Malmo ¨ Microbiology Biobank (since 1969).
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bank. The Swedish Institute for Infectious Disease Control has
performed a series of population-based, nationwide investigations
of the immunity against infections in the Swedish population [7].
For decades, Swedish Institute for Infectious Disease Control has
also served as reference laboratory for many microbiological
analyses. As a part of the quality control and documentation
system, part of the samples that have been analyzed have been
stored at 220uC. Samples have been stored since 1957 and
complete series of samples are stored since 1977. The biobank
included serum samples from 93 462 unique individuals (with valid
National Registration Numbers [NRNs] – individually unique
personal identifiers assigned to all Swedish residents shortly after
birth or immigration) collected between age 16 and 40. The
samples selected for the study cohort arrived in the biobank
between 1968-03-19 and 2001-12-31.
Malmo ¨ Microbiology Biobank. The biobank contains the
samples submitted to the Department of Clinical Microbiology at
MAS University Hospital in Malmo ¨, where saving of a part of
the sample has been necessary for clinical diagnostic and
documentation purpose. The majority of the samples are serum
samples that have been submitted for diagnosis of blood-borne
viral infections, e.g. hepatitis virus, (over 500,000 samples). About
100,000 samples in the biobank emanate from population-based
serological screening for viral infections and rubella immunity
during pregnancy. The population served is currently the entire
region of Ska ˚ne, where the Department of Clinical Microbiology is
currently the only clinical virological laboratory. The operation of
the biobank is certified by the Swedish National Accreditation
Agency and follows ISO17025 procedures. The Malmo ¨ Micro-
biology Biobank included serum samples from 374 598 unique
individuals (with valid NRNs) collected between age 16 and 40.
The samples selected for the study cohort arrived in the biobank
between 1969-02-10 and 2001-12-31.
Follow-up
Linkage to complete nationwide registers, including the Swedish
Cancer Register, Causes of Death Register and Migration
Register, provided follow-up data from serum collection until first
diagnosis of stomach cancer, emigration, death, or December 31,
2006, whichever occurred first. The NRNs, used both in the
biobanks and the registers, ensured precise matches. To verify the
validity of the NRNs, further linkage to the Total Population
Register was performed. If a NRN could not be found in the Total
Population Register, Causes of Death Register or Migration
Register, it was deemed to be invalid and the serum sample, along
with the record, was not included in our analysis. Stomach
adenocarcinoma cases were identified through the nationwide
Cancer Register, founded in 1958 and with an estimated
completeness of 96–98% [8,9]. The Cancer Register recorded
neoplasms using ICD-7 classification through the entire study
period. A separate code for gastric cancer in the cardia was
introduced first in 1969 and was widely used since 1970. The
histological type of each recorded tumour was also recorded by a
histology code, albeit these codes did not distinguish between
Laure ´n’s intestinal and diffuse types of adenocarcinoma [10]. In
order to reduce the possibility of misclassification of H. pylori
infection status associated with stomach cancer development,
stomach cancer cases occurring within 5 years of index serum
collection were disregarded. For each stomach cancer case we
selected 2 controls matched on age, sex, year of serum sample
collection and biobank using incidence density sampling.
Review of medical records
To further verify the diagnosis and specify the gastric subsite, all
medical records collected from corresponding treatment units
were reviewed by a specialist in gastrointestinal surgery (ON)
blinded to H. pylori status and earlier reported ICD code in the
Swedish Cancer Register.
Laboratory analysis
Immunoglobulin G antibodies against Hp-CSAs were measured
with an enzyme–linked immunosorbent assay (ELISA) (Biohit,
Finland). The sensitivity and specificity for the assay was reported
as 96% and 94%, respectively [11]. Antibodies against CagA were
measured with an immunoblot assay (Helicoblot 2.1, Genelabs
Diagnostics, Singapore) according to manufacturer’s instructions
[12].
Pepsinogen (PG) levels in sera were measured using an ELISA
method (Biohit, Finland) according to the manufacturer’s
instructions. Presence of severe or moderate corpus atrophic
gastritis was defined as PGI below 25 ug/l or PGI:PGII ratio less
than 3. The sensitivity and specificity was reported as 71% and
98% in a validation study performed in Sweden [13]. All
laboratory analyses were carried out in a blinded fashion by
trained personnel. The quality control samples provided with the
kits were included on each assay plates with additional quality
control samples using pooled serum samples from the laboratory.
Statistical analysis
The odds ratios (ORs) and their corresponding 95% confidence
intervals (95% CIs) of developing stomach adenocarcinoma
associated with H. pylori infection was estimated using conditional
logistic regression models. Since controls were individually
matched to the cases with regard to age, sex, calendar year of
serum collection, and biobank, these factors were inherently
adjusted for. All statistical analyses were performed using Stata/SE
9.2 (StataCorp, college Station, TX, USA). The study was
approved by the Regional Research Ethics Vetting Board in
Stockholm, Sweden.
Results
Figure 1 shows the flowchart for identification of stomach
adenocarcinoma cases. In total 105 stomach cancers (ICD-7 code
151) which occurred at least 5 years after blood sample collection
were identified during follow-up. Among these, 27 were excluded
due to either missing serum samples or the fact that the cancers
were found incidentally at autopsy. For the remaining 78 cases, we
successfully retrieved medical records related to cancer diagnosis
for 68 cases. After review, 9 cases were deemed to be tumors other
than stomach adenocarcinoma. Among the remaining 59 stomach
adenocarcinoma cases, 15 stomach adenocarcinoma cases were
determined to be cardia adenocarcinoma and 41 as non-cardia
stomach adenocarcinoma. In 3 stomach adenocarcinoma cases it
was not possible to determine the exact origin in the stomach.
Some basic characteristics of cases and their matched controls
are summarized in Table 1. As expected, there were no
differences in the sex distribution and mean age at blood sample
collection between cases and controls. The mean age at diagnosis
of stomach adenocarcinoma was 47.3 years (range 25–68). The
mean time between serum collection and stomach adenocarcino-
ma diagnosis was 16.5 years (range 5–33). Presence of severe or
moderate corpus atrophic gastritis at time of initial serum
collection was more common among stomach adenocarcinoma
cases (8.5%) as compared with matched controls (0.9%).
H. pylori and Stomach Cancer: A True Relationship?
PLoS ONE | www.plosone.org 2 March 2011 | Volume 6 | Issue 3 | e17404ORs for all stomach adenocarcinoma among subjects with Hp-
CSA antibodies (regardless of CagA serostatus) and antibodies
against CagA (regardless of Hp-CSA serostatus) were 4.1 (95% CI
1.9–8.5) and 3.5 (95% CI 1.7–7.1), respectively (Table 2). We
further analyzed data by combining Hp-CSA and CagA
antibodies, and used subjects seronegative for both as the
Figure 1. Flowchart for identifying stomach adenocarcinoma cases. In total 105 stomach cancers (ICD-7 code 151) which occurred at least 5
years after blood sample collection were identified during follow-up. Among these, 27 were excluded due to either missing serum samples or the fact
that the cancers were found incidentally at autopsy. For the remaining 78 cases, medical records related to cancer diagnosis for 68 cases were
successfully retrieved. After review, 9 cases were deemed to be tumors other than stomach adenocarcinoma. Among the remaining 59 stomach
adenocarcinoma cases, 15 stomach adenocarcinoma cases were determined to be cardia adenocarcinoma and 41 as non-cardia stomach
adenocarcinoma. In 3 stomach adenocarcinoma cases it was not possible to determine the exact origin in the stomach.
doi:10.1371/journal.pone.0017404.g001
Table 1. Characteristics of the stomach adenocarcinoma cases and their matched controls.
Characteristics Stomach adenocarcinoma cases (n=59) Controls (n=117)
Men (%) 30 (50.9) 60 (51.2)
Age at sample collection, mean (SD), range 30.8 (6.1), 16–40 30.9 (6.0), 16–40
Age at cancer diagnosis, mean (SD), range 47.3 (9.4), 25–68
Years between serum collection and cancer diagnosis, mean (SD), range 16.5 (7.2), 5–33
Severe or moderate corpus atrophy*, N (%) 5 (8.5) 1 (0.9)
* Defined as serum pepsinogen I,25 ug/l or pepsinogen I:II ratio ,3 at time of initial serum collection.
doi:10.1371/journal.pone.0017404.t001
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group, those seropositive with either Hp-CSA or CagA antibodies
had a more than 3-fold increased risk of developing stomach
adenocaricnoma. The increased risk was more pronounced among
the group seropositive with both Hp-CSA and CagA antibodies
(OR=5.5, 95% CI 2.3–12.9) (Table 2).
When analysis was limited to 41 cases of non-cardia stomach
adenocarcinoma, ORs were 17.1 (95% CI 4.0–72.9) and 10.9
(95% CI 3.2–36.9) among carriers of antibodies to Hp-CSAs and
CagA, respectively. The corresponding results for cardia adeno-
carcinoma were 0.5 (95% CI 0.1–2.8) and 0.6 (95% CI 0.2–2.5),
respectively (Table 2). Compared with the ‘clean’ reference
group, those seronegative for both Hp-CSA and CagA antibodies,
subjects seropositive with either Hp-CSA or CagA antibodies had
a close to 10-fold increased risk (95% CI 2.9–32.9), and the
increased risk further rose to close to 50-fold among those
seropositive with both antibodies (95% CI 5.8–407.4). The
corresponding results for cardia adenocarcinoma were 0.8 (95%
CI 0.2–2.7) and 0.3 (95% CI 0.03–2.6), respectively (Table 2).
Discussion
Although H. pylori was classified as a class I carcinogen for
stomach cancer by the International Agency for Research on
Cancer (IARC) already in 1994 [14], the strength of the
association remains uncertain. In an early meta-analysis of 42
studies that were typically of a cross-sectional nature (with H. pylori
diagnosis at time of cancer diagnosis), the summary odds ratio was
only 2.04 [15]. This is probably due to the fact that stomach
adenocarcinoma develops late in life (55+), and the histological
changes in the stomach during cancer development might lead to
spontaneous disappearance of the bacteria. H. pylori have been
shown to promote the production of inflammatory mediators such
as IL-1b and TNF-a, both potent suppressors of stomach juice
secretion. The increase in stomach pH may lead to spread of H.
pylori from the antrum to the corpus, resulting in enhanced
inflammation in the mucosa of the corpus, followed by parietal cell
destruction and irreversible hypochlorhydria [2,16].
Already in 1994 a combined analysis of 3 prospective studies
found that excess risks increased with increasing time window
between sample collection and cancer diagnosis [17]. This finding
was corroborated later by a pooled analysis of 12 prospective
studies [18], in which a six-fold increased risk for non-cardia
adenocarcinoma was found in patients whose samples were
collected 10 years or more before cancer diagnosis, while the
relative risk within 10 years after serotesting was 2.4. Similarly, in
the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC)
prospective cohort study, a close to 8-fold relative risk for non-
cardia stomach cancer associated with H. pylori infection was
reported [19]. H. pylori strains containing the CagA gene are known
to cause more extensive inflammation in the stomach mucosa and
antibodies against CagA persist long after eradication [20,21]. In a
Swedish population based case-control study [22], when Hp-
CSA-/CagA+ subjects (presumably with ‘‘burnt-out’’ H. pylori
infection) were removed from the seronegative reference group,
subjects seropositive with Hp-CSAs had an OR of 21.0. In
particular, the group with Hp-CSA-/CagA+, compared with the
reference group seronegative with both tests, has an odds ratio as
high as 68.0. This is consistent with a recent Japanese cohort study
among middle-aged subjects [23]. There, a more than 100-fold
excess risk of stomach cancer was noted in the group seronegative
with H. pylori antibodies but with a low pepsinogen I:II ratio. Some
studies even suggested that H. pylori infection might be a necessary
cause for non-cardia adenocarcinoma. In a small case-control
study performed in Germany, after excluding cases with blood
samples collected more than 90 days after gastrectomy, T4 stage,
Hp-/CagA+, or borderline IgG results, all the remaining 32 non-
cardia stomach adenocarcinoma cases were seropositive with H.
pylori infection [24]. Similarly, in a small cohort study, in which H.
pylori status was ascertained by histological examination, rapid
urease test, and serologic test, 3% of infected subjects but none of
the uninfected developed a stomach cancer, after a mean follow-
up time of 7.8 years [25]. Another study conducted in Taiwan with
a similar study design also reported none of stomach malignancies
detected among the uninfected subjects after a mean follow-up of
6.3 years [26].
In summary, several of the more recent studies suggested that
the strength of the H. pylori-noncardia stomach adenocarcinoma
association might range between a 6-fold to infinite (necessary
cause). However, previous studies have various limitations,
including small sample size, blood samples collected at old age
or at cancer diagnosis, and misclassification of anatomic site of
stomach cancer. Our study, based on two large biobanks in
Sweden, was able to identify a relative large cohort of subjects,
who donated blood samples between ages 16–40, which is the best
time window to capture the lifetime occurrence of the infection, as
acquisition of the infection almost invariably occurs before
adulthood. Further, we retrieved and reviewed medical records
Table 2. H. pylori -CSAs and CagA seropositivity and the risk of stomach adenocarcinoma overall, cardia site and non-cardia site.
Stomach adenocarcinoma Cardia adenocarcinoma Non-cardia adenocarcinoma
Serological test results Case Control OR*(95% CI) Case Control OR*(95% CI) Case Control OR*(95% CI)
Hp-CSAs antibodies Negative 20 76 Ref. 12 21 Ref. 6 51 Ref.
Positive 39 41 4.1 (1.9–8.5) 3 9 0.5 (0.1–2.8) 35 30 17.1 (4.0–72.9)
CagA antibodies Negative 19 70 Ref. 11 19 Ref. 7 49 Ref.
Positive 40 47 3.5 (1.7–7.1) 4 11 0.6 (0.2–2.5) 34 32 10.9 (3.2–36.9)
Hp-CSAs – CagA
antibodies
Hp-CSAs and CagA
antibodies negative
15 61 Ref. 10 18 Ref. 4 41 Ref.
Hp-CSAs or CagA
antibodies positive
44 56 3.3 (1.6–6.7) 5 12 0.8 (0.2–2.7) 37 40 9.7 (2.9–32.9)
Hp-CSAs and CagA
antibodies positive
35 32 5.5 (2.3–12.9) 2 8 0.3 (0.03–2.6) 32 22 48.5 (5.8–407.4)
* Odds ratios (ORs) were derived from conditional logistic regression models.
doi:10.1371/journal.pone.0017404.t002
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noncardia origin in all but 3 cases. Our results suggested that the
strength of the association between H. pylori infection and risk of
non-cardia stomach adenocarcinoma was greater than what was
reported before in some previous prospective studies among older
subjects. However, our data do not provide clear support for the
hypothesis that H. pylori is a necessary cause of non-cardia stomach
adenocarcinoma. Despite small number of cardia adenocarcino-
ma, our results were consistent with previous report of a null
association with H. pylori infection in low-risk areas [27].
Despite our efforts to capture H. pylori infection status in the best
time window, we could not exclude the possibility of misclassifi-
cation of H. pylori infection status. Several lines of evidence support
this suspicion, as among the four non-cardia adenocarcinoma
cases without any evidence of H. pylori infection, one had
moderate/severe corpus atrophy at time of serum sampling,
suggesting (albeit not proving) previous occurrence of H. pylori at
some point. Linkage to the Inpatient Register also found that this
patient had been hospitalized for viral hepatitis before the date of
blood sampling. For the other 3 cases, one had been hospitalized
for chronic nephritis before blood sampling, which might also lead
to inaccurate measurement of H. pylori antibodies. Another
limitation of our study is that, due to the age structure of our
cohort subjects, most stomach cancer cases were of young age.
The association between H. pylori infection and stomach cancer
might differ as diffuse type is more common among young cases,
although previous studies found similar associations for both
diffuse and intestinal types [19,22]. Further, although the cases
and controls were matched on age, sex, calendar year of serum
collection and biobank, we lacked the information on other
potential confounders, like socioeconomic status, smoking and
diet, etc. Thus, the possibility of residual confounding cannot not
be ruled out.
Our results add confidence to the conclusion that H. pylori
infection is a much stronger risk factor for non-cardia stomach
adenocarcinoma than initially realized, but it is probably not a
necessary cause. However, since misclassification of H. pylori status
may have occurred also in this study, the association might be even
stronger than indicated by our data.
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